Initiаl Pоst оn Hyperlipidemiа Hyperlipidemiа is a medical cоndition characterized by abnormally high levels of lipids, including cholesterol and triglycerides, in the blood. Lipids are fats in the bloodstream, commonly divided into cholesterol and triglycerides. Cholesterol circulates in the bloodstream and is involved in the structure and function of cells. Triglycerides is the energy used either immediately or stored in fat cells which are manufactured in the liver from the foods, or by being absorbed in the intestine (Singh, 2022). High levels of lipids, cholesterol, and triglycerides are a risk factor for atherosclerosis. Atherosclerosis may also be associated with elevated LDL or low-density lipoprotein cholesterol, an abnormal amount of lipids in the blood, elevated total cholesterol or triglycerides, or low HDL or high-density lipoprotein cholesterol (Singh, 2022). The etiology of hyperlipidemia can be separated into two types, which are primary and secondary. Primary hyperlipidemia is the result of genetic problems, such as a mutation within the receptor protein. Whereas secondary hyperlipidemia is the result of other underlying diseases such as diabetes, chronic alcoholism, and drugs such as beta-blockers (Singh, 2022). Hyperlipidemia includes changes in lifestyle habits, mainly one's diet. Specifically with a fat intake greater than forty percent of total calories, saturated fat intake greater than ten percent of total calories, and cholesterol intake greater than three hundred milligrams per day. Other risk factors include hypertension, diabetes, kidney disease, pregnancy, obesity, smoking, chronic alcoholism, underactive thyroid gland, polycystic ovarian syndrome, and stress (Singh, 2022). Other factors include higher levels of estrogen, drugs such as diuretics, beta-blockers, and medicines used to treat depression. Age, gender, and hereditary factors also play an important role in the amount of cholesterol the body makes. Physical assessment and clinical manifestations consist of the culmination of the elevation and deposition of LDL-derived cholesterol in tendons and arteries, as well as assessing the accumulation of chylomicrons which are produced in the intestines. Other findings include abdominal pain, pancreatitis, xanthoma striata palmaris, and peripheral polyneuropathy (Singh, 2022). The diagnosis of hyperlipidemia culminates in a medical history, physical exam, and lipid panel blood test. To start there needs to be a measurement of total plasma cholesterol and triglyceride levels through fasting and non-fasting serum levels. Non-fasting triglyceride levels related to hyperlipidemia are typically seen elevated, coming in around one hundred and seventy-five or higher. While fasting serum levels related to hyperlipidemia are typically around one hundred and fifty (Yanai et al., 2023). Other methods of measuring cholesterol include using an immuno-affinity gel mixture, which absorbs lipoproteins. From here the solid phase of lipoproteins is extracted and measured. The treatment of hyperlipidemia involves dietary and drug therapies. Initial treatment involves restricting the dietary intake of cholesterol and saturated fat. Drug therapy is instituted when further lowering of cholesterol levels is desired. The objective of dietary management is to decrease the intake of total fat, saturated fatty acids, and cholesterol progressively until the desirable body weight is achieved. This often involves reducing saturated fat intake to seven percent of daily calories, reducing total fat intake to twenty-five to thirty-five percent of daily calories, limiting daily cholesterol to less than two hundred milligrams per day, alongside consuming twenty to thirty grams of soluble fiber daily (Singh, 2022). Drug therapies consist of antihyperlipidemic agents such as lovastatin, clofibrate, nicotinic acid, D-thyroxine, cholestyramine, probucol, and heparin (Chinn, 2024). Lovastatin is a specific type of bet-dihydroxy acid that blocks the synthesis of cholesterol by inhibiting the enzyme responsible for the biosynthesis of cholesterol. Similarly, clofibrate blocks the synthesis of cholesterol prior to the HMG-CoA stage, or the intermediate molecule that controls the conversion of cholesterol. The blockage of cholesterol before the HMG-CoA stage inhibits triglyceride formation as well. Nicotinic acid inhibits the synthesis of acetyl coenzyme, which is the building block for cholesterol (Chinn, 2024). In return, this blocks the synthesis of cholesterol and triglycerides. However, to be effective, Nicotinic acid must be taken in large amounts. The previously listed medications block the synthesis of cholesterol, whereas d-thyroxine, cholestyramine probucol, and heparin work in a different way. D-thyroxine promotes metabolism in the liver, transforming it into a water-soluble bile so that it may be eliminated from the body. This is brought forth by binding cholestyramine to the bile aids so that they may not be reabsorbed into the body, but may be eliminated in the feces. Probucol on the other hand is an antioxidant that acts as a free radical scavenger (Chinn, 2024). Probucol inhibits the production of LDL or low-density lipoprotein. This process occurs by the removal of bile acids from the body causing the liver to use more cholesterol to produce new bile acid, leading to a decrease in LDL cholesterol levels. Lastly, there is heparin, which promotes the hydrolysis of triglycerides as it activates lipoprotein lipase and, in return, refuses lipidemia (Chinn, 2024). In conclusion, hyperlipidemia is a condition characterized by high levels of lipids, such as cholesterol and triglycerides, in the blood, increasing the risk of atherosclerosis. It can be classified into primary hyperlipidemia, which results from genetic factors, and secondary hyperlipidemia, caused by conditions like diabetes, obesity, and hypertension. Contributing factors include poor diet, obesity, smoking, stress, and certain medications. Physical signs include xanthomas and pancreatitis, while diagnosis involves a lipid panel test. Treatment includes dietary changes, such as reducing fat and cholesterol intake, and drug therapies. References Chinn, L. J. (2024). Hyperlipidemia. EBSCO Research Starters. https://www.ebsco.com/research-starters/health-and-medicine/hyperlipidemia Singh, P. K. . (2022). Hyperlipidemia: Etiology and Possible Control Through Homoeopathic Remedies: Research Article- DOI: 10.23953/cloud.ijaayush.518. International Journal of Advanced Ayurveda, Yoga, Unani, Siddha and Homeopathy, 11(1), pp.696–700. Retrieved from https://www.cloudjl.com/index.php/Ayurveda/article/view/47 Yanai, H., Adachi, H., Hakoshima, M., & Katsuyama, H. (2023). Postprandial Hyperlipidemia: Its Pathophysiology, Diagnosis, Atherogenesis, and Treatments. International Journal of Molecular Sciences, 24(18), 13942. https://doi.org/10.3390/ijms241813942